Teclistamab联合达雷妥尤单抗双免疫方案治疗复发难治多发性骨髓瘤:TRIMM-2研究
TRIMM-2为1b期研究,评估按体重给药Teclistamab联合达雷妥尤单抗治疗复发难治多发性骨髓瘤的安全性和疗效。
要点
- 按体重给药Teclistamab联合达雷妥尤单抗在RRMM中显示深度持久缓解,ORR 68.9%。
- 3/4级治疗中出现不良事件发生率93.4%,7例死于不良事件,需重视感染管理。
- 固定剂量队列因致命感染安全信号提前终止,所有患者转为按体重给药。
核心结论
- 按体重推荐2期剂量Teclistamab联合达雷妥尤单抗的全免疫组合方案在复发难治多发性骨髓瘤中显示深度且持久的缓解,安全性特征明确。
研究设计与样本
- 1b期TRIMM-2研究,纳入复发难治多发性骨髓瘤患者,要求既往≥3线治疗或对蛋白酶体抑制剂和免疫调节药物双重难治,允许既往抗CD38暴露。
- 主要终点为安全性,次要终点包括总缓解率和缓解持续时间,无进展生存为探索性终点。
主要发现
- 最常见治疗中出现不良事件为感染、细胞因子释放综合征、中性粒细胞减少和贫血;3/4级不良事件发生率93.4%,7例死于不良事件。
- 未发生剂量限制性毒性。
- 总缓解率68.9%,完全缓解及以上44.3%,中位缓解持续时间未达到。
- 中位无进展生存26.3个月。
- 探索固定剂量Teclistamab(100-300 mg)的队列因发现致命感染安全信号提前终止,出于谨慎所有患者转为按体重给药。
关键数值与推荐
- 推荐2期剂量为Teclistamab 1.5 mg/kg每周一次或3.0 mg/kg每两周一次,联合达雷妥尤单抗按获批方案皮下给药。
- 总缓解率68.9%(完全缓解及以上44.3%),中位无进展生存26.3个月。
- 3/4级治疗中出现不良事件发生率93.4%,7例死于不良事件。
临床怎么用
- 按体重推荐2期剂量Teclistamab联合达雷妥尤单抗可作为复发难治多发性骨髓瘤的全免疫双药方案。
- 治疗中需加强感染管理,包括早期免疫球蛋白替代。
- 固定剂量Teclistamab(100-300 mg)因致命感染安全信号不推荐使用,应使用按体重给药。
局限性
- 固定剂量队列提前终止,相关数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Teclistamab is the first approved B-cell maturation antigen×CD3 bispecific antibody with weight-based dosing for triple-class-exposed relapsed/refractory multiple myeloma (RRMM). We evaluated the safety and efficacy of teclistamab combined with the anti-CD38 monoclonal antibody daratumumab in the phase 1b TRIMM-2 study. Eligible patients had RRMM (≥3 prior lines of therapy [LOT] or were double-refractory to a proteasome inhibitor and immunomodulatory drug); prior anti-CD38 exposure was permitted. Patients received subcutaneous daratumumab per approved schedule plus weight-based or fixed-dose subcutaneous teclistamab. The primary endpoint was safety; secondary endpoints included overall response rate (ORR) and duration of response (DOR). Progression-free survival (PFS) was an exploratory endpoint. Sixty-one patients received the weight-based recommended phase 2 doses (RP2D; teclistamab 1.5 mg/kg QW or 3.0 mg/kg Q2W); median number of prior LOTs was 5 (range, 1-14). Median follow-up was 12.0-months. The most common treatment-emergent adverse events (TEAEs) were infections, cytokine release syndrome, neutropenia, and anemia; grade 3/4 TEAEs occurred in 93.4% and 7 died from TEAEs. No dose-limiting toxicities occurred. ORR was 68.9% (complete response or better, 44.3%); median DOR was not reached. Median PFS was 26.3 months. A cohort exploring fixed-dose teclistamab (100-300 mg) ended prematurely after a safety signal for fatal infections was identified; out of an abundance of caution, all patients were switched to weight-based dosing. In conclusion, the fully immune-based combination of weight-based RP2D teclistamab plus daratumumab demonstrated deep and durable responses, with a well-characterized safety profile. Results highlight the importance of infection management, including early immunoglobulin replacement. Registered at ClinicalTrials.gov: NCT04108195.
引用
- Rodriguez-Otero P, Morillo D, D'Souza A, et al. Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study. Blood Adv. 2026. PMID: 42685673. doi:10.1182/bloodadvances.2026020648
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。